Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linezolid, critical characteristics

Hamel1, Stapert, Moerman

  • 1Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49007, USA.

Infection
|March 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Malaria.

Buffalo medical and surgical journal·2023
Same author

A hereditary disorder of cornification and multiple congenital defects in five Rottweiler dogs.

Veterinary dermatology·2021
Same author

Characterization and management of a Jack Russell terrier with congenital ichthyosis.

Veterinary dermatology·2021
Same author

Error in Reference List. Multigene Panel Testing in Oncology Practice: How Should We Respond.

JAMA oncology·2015
Same author

Cirsoid annevrysme and mental disorders.

Revue medicale de Nancy·2010
Same author

Parkinsonism and mental disorders in a traumatized syphilitic.

Revue medicale de Nancy·2010
Same journal

Metagenomic next-generation sequencing assists in identifying neurosyphilis: a case series.

Infection·2026
Same journal

Chlamydia trachomatis infection among women with spontaneous abortion in Uganda: burden, clinical presentation, and associated factors in a hospital-based cross-sectional study.

Infection·2026
Same journal

Performance of ultra-sensitive electrochemiluminescence LAM assay for diagnosing tuberculosis in HIV-negative individuals: a multicentre, prospective diagnostic study.

Infection·2026
Same journal

Prehospital blood cultures in suspected sepsis: no need to wait until hospital arrival!

Infection·2026
Same journal

Epidemiological trends of invasive Streptococcus pyogenes infections in Catalonia, 2022-2024: a two-year analysis.

Infection·2026
Same journal

Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort.

Infection·2026
See all related articles

Linezolid, a novel oxazolidinone antibiotic, shows potent activity against gram-positive bacteria with slow resistance development. It is orally and intravenously effective, demonstrating excellent bioavailability and suitability for twice-daily dosing.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Linezolid is the first oxazolidinone antibiotic approved for human use.
  • Oxazolidinones possess a unique mechanism of action, inhibiting bacterial protein synthesis initiation.
  • This novel mechanism ensures no cross-resistance with existing antibacterial agents.

Purpose of the Study:

  • To highlight key characteristics of linezolid.
  • To evaluate its efficacy and pharmacokinetic profile.
  • To assess its potential as a treatment for gram-positive bacterial infections.

Main Methods:

  • Review of existing data on linezolid's mechanism of action, resistance patterns, and spectrum of activity.
  • Comparison of in vitro activity with vancomycin.

Related Experiment Videos

  • Evaluation of oral and intravenous efficacy in mouse models.
  • Analysis of human pharmacokinetic data for dosing predictions.

    • Main Results:

    • Linezolid exhibits activity primarily against gram-positive pathogens, comparable to vancomycin in vitro.
    • Laboratory studies indicate very slow development of resistance.
    • Oral linezolid demonstrated 100% bioavailability and efficacy in mouse models, equivalent to subcutaneous vancomycin.
    • Human dosing studies suggest suitability for twice-daily administration with blood concentrations exceeding MIC90 for key pathogens.

    Conclusions:

    • Linezolid represents a significant advancement in treating gram-positive bacterial infections.
    • Its novel mechanism, favorable pharmacokinetic profile, and low resistance potential make it a valuable therapeutic option.
    • Linezolid's oral bioavailability and efficacy support its use as an alternative to intravenous therapy.